Alzchem Group AG

Alzchem Group AG: Dr. Georg Weichselbaumer, buy

Alzchem Group AG: Andreas Lösler, buy

Alzchem Group AG: Herr Andreas Niedermaier, buy

Alzchem Group AG: Klaus Dieter Englmaier, buy

Alzchem Group AG: Klaus Dieter Englmaier, buy

Alzchem Group AG: Klaus Dieter Englmaier, buy

Alzchem Group new partner of FC Bayern Basketball

Alzchem Group AG reports 36.4% EBITDA growth to EUR 76.8 million – strong earnings performance continues in the first nine months of 2024

Alzchem Group AG: Alzchem Group AG resolves to buy back shares for up to EUR 6 million

Provision of balancing energy: Alzchem Group AG supports grid stability through flexible load control

Alzchem Group AG plans to double nitroguanidine production capacity in Germany

Alzchem Group AG: Doubling of nitroguanidine production capacities planned in Germany; preliminary contract for site search in the USA concluded

Alzchem Group AG set to join the SDAX on October 2, 2024

Alzchem Group AG: Continued strong growth in Specialty Chemicals business leads to significant EBITDA increase of 41.2% to EUR 51.9 million in the first half of 2024

Alzchem Group AG raises forecasts for EBITDA and EBITDA margin in fiscal year 2024

Alzchem Group AG: Three Alzchem climate projects receive public funding of around EUR 850 thousand

Alzchem Group AG receives strong support from shareholders at Annual General Meeting; dividend increase to EUR 1.20 per share approved

Alzchem Group AG seamlessly builds on strong business performance in 2023 with EBITDA growth of 31.7% in first quarter 2024

Alzchem Group AG: Bekanntmachung der Einberufung zur Hauptversammlung am 07.05.2024 in Trostberg mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG

Alzchem Group AG: Alzchem Group AG receives EUR 34.4 million in EU funding

Crearene AG and Alzchem Group AG: Successful addition of creatine to dialysis patient treatments

Alzchem Group AG: EBITDA increase of 32.4 % to EUR 81.4 million – continuing on the road to success